Cargando…
Sildenafil citrate for the management of fetal growth restriction and oligohydramnios
Fetal growth restriction (FGR) and preeclampsia are the major causes of neonatal morbidity and mortality, which affect up to 8% of all pregnancies. The pathogenesis in FGR is an abnormal trophoblastic invasion leading to compromised uteroplacental circulation. However, in spite of this understanding...
Autores principales: | Choudhary, Rana, Desai, Kavita, Parekh, Hetal, Ganla, Kedar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984996/ https://www.ncbi.nlm.nih.gov/pubmed/27563258 http://dx.doi.org/10.2147/IJWH.S108370 |
Ejemplares similares
-
Sildenafil Citrate: Novel Therapy in the Management of Ovarian Torsion
por: Ganla, Kedar N., et al.
Publicado: (2019) -
Sildenafil Citrate in Fetal Growth Restriction
por: Panda, Subrat, et al.
Publicado: (2014) -
Sildenafil citrate and uteroplacental perfusion in fetal growth restriction
por: Dastjerdi, Marzieh Vahid, et al.
Publicado: (2012) -
Massive Subchorionic Thrombohematoma (Breus' Mole) Associated with Fetal Growth Restriction, Oligohydramnios, and Intrauterine Fetal Death
por: Miyagi, Miyuki, et al.
Publicado: (2019) -
Potential effects of transdermal nitric oxide donor on fetal growth restriction and oligohydramnios: A case report
por: Murata, Tsuyoshi, et al.
Publicado: (2020)